Richter CEO: the company achieved good performance in the first quarter

By: Trademagazin Date: 2025. 05. 13. 10:03

Richter achieved a good performance in the first quarter and confirms its previous forecast, according to which the growth for the whole year, excluding exchange rate effects, is expected to be around 10 percent for both revenues and earnings before interest and taxes (EBIT), said CEO Gábor Orbán at a press conference evaluating the first quarter results in Budapest on Tuesday.

He highlighted that they achieved results in line with the analyst consensus and are satisfied with all important indicators. The 10 percent increase in sales is a particularly good performance in light of the fact that they started from a high base, he said. The exchange rate effect in the first quarter, primarily the change in the dollar exchange rate, also helped the results.

He explained that

all business lines and all geographical regions were able to grow. The biotechnology business line saw double-digit growth, which he called outstanding, just as the 12 percent growth in the Gen Med business line is also an important result. Richter’s research and development (R&D) expenditure is continuously increasing, rising by 4.5 percent to HUF 23.8 billion in the first quarter, which accounted for 11 percent of sales. This is the highest value in the region

– he pointed out.

CFO László Kovács said that net profit was HUF 68 billion, which is unchanged compared to the same period of the previous year. Free cash flow (before M&A activity) amounted to HUF 60 billion in the first quarter of 2025, which is an increase of 14 percent. The general meeting approved the board of directors’ proposal to pay a dividend of HUF 93 billion from the profit after tax for 2024, the payment will take place in June 2025, he added.

Gábor Orbán announced that Richter has acquired a significant stake and entered into a business development cooperation in Granata Bio, a US-based company focused on reproductive healthcare. As part of the transaction, Richter will become a significant investor in Granata Bio and will receive a seat on Granata Bio’s board of directors. The partnership aligns with Richter’s commitment to expand its presence in the United States and strengthen the strategy of its Women’s Health Care (WHC) business.